JP2014524936A5 - - Google Patents

Download PDF

Info

Publication number
JP2014524936A5
JP2014524936A5 JP2014523106A JP2014523106A JP2014524936A5 JP 2014524936 A5 JP2014524936 A5 JP 2014524936A5 JP 2014523106 A JP2014523106 A JP 2014523106A JP 2014523106 A JP2014523106 A JP 2014523106A JP 2014524936 A5 JP2014524936 A5 JP 2014524936A5
Authority
JP
Japan
Prior art keywords
group
formula
pharmaceutically acceptable
prodrug
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014523106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524936A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048820 external-priority patent/WO2013016727A1/en
Publication of JP2014524936A publication Critical patent/JP2014524936A/ja
Publication of JP2014524936A5 publication Critical patent/JP2014524936A5/ja
Pending legal-status Critical Current

Links

JP2014523106A 2011-07-28 2012-07-30 システインプロドラッグ Pending JP2014524936A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512751P 2011-07-28 2011-07-28
US61/512,751 2011-07-28
PCT/US2012/048820 WO2013016727A1 (en) 2011-07-28 2012-07-30 Cysteine prodrugs

Publications (2)

Publication Number Publication Date
JP2014524936A JP2014524936A (ja) 2014-09-25
JP2014524936A5 true JP2014524936A5 (enExample) 2015-09-03

Family

ID=47601579

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014523106A Pending JP2014524936A (ja) 2011-07-28 2012-07-30 システインプロドラッグ

Country Status (5)

Country Link
US (2) US9457014B2 (enExample)
EP (1) EP2736890A4 (enExample)
JP (1) JP2014524936A (enExample)
CA (1) CA2842106A1 (enExample)
WO (1) WO2013016727A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013016727A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
US20130338165A1 (en) * 2012-06-15 2013-12-19 Promentis Pharmaceuticals, Inc. Use of Compounds Elevating Glutathione Levels for the Treatment of Parkinson's Disease
US20150045312A1 (en) * 2013-08-12 2015-02-12 Promentis Pharmaceuticals, Inc. Use of Compounds Elevating Glutathione Levels for the Treatment of Autism, Autistic Spectrum Disorders and Fragile X Syndrome
LT3066089T (lt) 2013-11-08 2020-02-25 Promentis Pharmaceuticals, Inc. Pakeistieji n-acetil-l-cisteino dariniai ir giminingi junginiai
EP3194027B1 (en) * 2014-09-15 2026-02-11 Sound Pharmaceuticals Incorporated Compositions for use in treating psychotic disorders
HUE069280T2 (hu) 2016-05-18 2025-02-28 Sound Pharmaceuticals Incorporated Ebselen a Meniere-kór kezelésére történõ felhasználásra
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
WO2020142450A1 (en) * 2018-12-31 2020-07-09 Zymergen Inc. Polymer compositions comprising compounds derived from biology
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
CN113024473B (zh) * 2021-04-13 2022-08-23 陕西慧康生物科技有限责任公司 一种含有半胱氨酸的环二肽的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT995110B (it) * 1973-08-01 1975-11-10 Snam Progetti Procedimento per la produzione di composti eterociclici e prodotti ottenuti
JPS6016989A (ja) * 1983-07-06 1985-01-28 Shionogi & Co Ltd オキソ飽和異項環カルボンアミドセフエム化合物
US5298516A (en) * 1991-03-27 1994-03-29 Sankyo Company, Limited Thiazolidone compounds and method of using the same as a vasodilator
AU682894B2 (en) 1993-10-28 1997-10-23 Institut National De La Recherche Agronomique Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
US6413999B1 (en) * 1999-08-17 2002-07-02 University Of Saskatchewan Technologies Inc. Treatment for acute physical insult to the central nervous system
US7829709B1 (en) * 2007-08-10 2010-11-09 Marquette University Cysteine prodrugs to treat schizophrenia and drug addiction
EP2252596B1 (en) * 2008-02-07 2016-12-28 Marquette University Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings
WO2013016727A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs

Similar Documents

Publication Publication Date Title
JP6804790B1 (ja) N4−ヒドロキシシチジンおよび誘導体ならびにそれらに関連する抗ウイルス用途
JP2015505296A5 (enExample)
JP2017519781A5 (enExample)
JP2017514830A5 (enExample)
HRP20211224T1 (hr) Derivati pirimidina za liječenje virusnih infekcija
JP2009501732A5 (enExample)
US20210002295A1 (en) Small molecule degraders that recruit dcaf15
JP2008513516A5 (enExample)
RU2015117251A (ru) Новые соединения
HRP20221389T1 (hr) Inhibitori bromodomena
RS61064B1 (sr) Modulatori proteina jezgra hepatitisa b
JP2015520140A5 (enExample)
JP2020502092A5 (enExample)
US10059670B2 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
HRP20161577T1 (hr) Inhibitori replikacije virusa gripe
HRP20171720T1 (hr) Derivati pirolo [3,2-d] pirimidina za liječenje virusnih infekcija i drugih bolesti
JP2017533968A5 (enExample)
JP2013514980A5 (enExample)
JP2017525668A5 (enExample)
JP2012519691A5 (enExample)
CN107759585A (zh) 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
JP2002030084A5 (enExample)
JP2019526546A5 (enExample)
JP2012504560A5 (enExample)